TheraVet S.A.: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
09 Août 2021 - 5:45PM
Business Wire
Regulatory News:
TheraVet S.A. (ISIN code: BE0974387194 – symbol : ALVET)
(Paris:ALVET) (Brussels:ALVET), a pioneering company in the
management of osteoarticular diseases in pets, provides the number
of shares outstanding and total number of voting rights (article
L233-8-II of the French Commercial Code and Article 223-16 of the
General Regulations of the AMF).
Date
Number of shares
outstanding
Total voting rights
Total gross (1)
Total net (2)
July 31, 2021
3 223 936
3 223 936
3 223 936
(1) The total number of gross (or “theoretical”) voting rights
is used as the basis for calculating threshold crossings. In
accordance with Article 223-11 of the AMF General Regulations, this
number is calculated on the basis of all shares to which voting
rights are attached, including those for which voting rights have
been suspended.
(2) The total number of net (or “exercisable at a Shareholders’
Meeting”) voting rights is calculated without taking into account
shares for which voting rights have been suspended. It is released
in order to ensure that the public is properly informed, in
accordance with the recommendation made by the AMF on 17 July
2007.
About TheraVet SA TheraVet is a veterinary biotechnology
company specialising in osteoarticular treatments for animals. The
Company develops targeted, safe and effective treatments to improve
the quality of life of pets suffering from osteoarticular diseases.
For pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris et Brussels, its head office is in
Jumet, Belgium, and it has a subsidiary in the US. For more
information, visit www.thera.vet
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210809005519/en/
TheraVet Sabrina Ena Chief Operating Officer
sabrina.ena@thera.vet Tel: +32 (0) 71 18 32 49
Julie Winand Chief Corporate Officer julie.winand@thera.vet Tel:
+32 (0) 71 18 32 49
NewCap Investor Relations and Financial Communications
Louis Tilquin / Olivier Bricaud theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024